Autonomix Medical, Inc. (AMIX)
AMIX moved a median of -0.43% 30 minutes after news, and -1.50% by the close. How AMIX actually reacts to news — the realized, point-in-time move the market made, measured across 237 labeled events over the last three years with zero look-ahead.
AMIX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 234 |
| 30-min | -0.43% | 44% | 237 |
| 60-min | -1.13% | 36% | 237 |
| to close | -1.50% | 38% | 233 |
| Middle 50% of AMIX reactions | -3.01% to +1.50% |
|---|---|
| Median reaction (30-min) | -0.43% |
| Measured reactions | 237 |
Half of all Autonomix Medical, Inc. news events land between -3.01% and +1.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AMIX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AMIX's baseline. Nothing else.
Recent AMIX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation | Press release | GlobeNewswire | -4.01% | -5.26% | |
| Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance | Press release | GlobeNewswire | -0.49% | +0.00% | |
| Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform | Press release | GlobeNewswire | +0.95% | +0.49% | |
| Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors | Press release | GlobeNewswire | +0.00% | +3.00% | |
| Form 8-K Autonomix Medical, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.00% | |
| Form EFFECT Autonomix Medical, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +3.00% | |
| Form DEF 14A Autonomix Medical, Inc. For: Oct 29 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.17% | |
| Form DEFA14A Autonomix Medical, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.17% | |
| Form PRE 14A Autonomix Medical, Inc. For: Oct 29 | SEC filing · Form PRE | SEC EDGAR | +2.69% | +2.46% | |
| Form S-3 Autonomix Medical, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.69% | +2.46% | |
| Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 | Press release | GlobeNewswire | +1.28% | +1.50% | |
| Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery | Press release | GlobeNewswire | +1.04% | -5.34% | |
| Form 8-K Autonomix Medical, Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -0.48% | -9.34% | |
| Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules | Press release | GlobeNewswire | +8.29% | -5.39% | |
| Form 10-Q Autonomix Medical, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.13% | -8.65% | |
| Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission | Press release | GlobeNewswire | +4.88% | -13.89% | |
| Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award | Press release | GlobeNewswire | -2.52% | — | |
| Form EFFECT Autonomix Medical, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.22% | -11.81% | |
| Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy | Press release | GlobeNewswire | +16.67% | — | |
| Form 8-K Autonomix Medical, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +3.77% | |
| Form S-3 Autonomix Medical, Inc. | SEC filing · Form S-3 | SEC EDGAR | +37.30% | +5.79% | |
| Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study | Press release | GlobeNewswire | -4.33% | -15.61% | |
| Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform | Press release | GlobeNewswire | +0.55% | -3.05% | |
| Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform | Press release | GlobeNewswire | +0.00% | -1.91% | |
| Form 8-K Autonomix Medical, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | -3.15% | |
| Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | -1.95% | -3.53% | |
| Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant | Press release | GlobeNewswire | +1.00% | -4.01% | |
| Form 8-K Autonomix Medical, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | — | +1.55% | |
| Form 8-K Autonomix Medical, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -14.13% | -3.87% | |
| Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change | Press release | GlobeNewswire | +1.43% | +2.65% | |
| Autonomix Announces Reverse Stock Split | Press release | GlobeNewswire | +1.43% | +2.65% | |
| Form 10-K/A Autonomix Medical, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.54% | |
| Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology | Press release | GlobeNewswire | -2.87% | -5.61% | |
| Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine | Press release | GlobeNewswire | +0.03% | +3.31% | |
| Form 10-K Autonomix Medical, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | -2.63% | +4.96% | |
| Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation | Press release | GlobeNewswire | -7.57% | +2.72% | |
| Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation | Press release | GlobeNewswire | +2.79% | -1.22% | |
| Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation | Press release | GlobeNewswire | -2.79% | -8.13% | |
| Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026 | Press release | GlobeNewswire | -1.26% | -0.91% | |
| Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026 | Press release | GlobeNewswire | -2.65% | -0.65% | |
| Form S-8 Autonomix Medical, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.10% | -0.03% | |
| Autonomix Medical to Present at LSI USA ’26 | Press release | GlobeNewswire | +1.82% | +0.50% | |
| Autonomix Medical Selected for Best Innovation Competition at CRT 2026 | Press release | GlobeNewswire | -0.21% | +2.99% | |
| Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis | Press release | GlobeNewswire | +0.00% | +4.57% | |
| Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation | Press release | GlobeNewswire | -1.30% | +8.92% | |
| Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation | Press release | GlobeNewswire | -1.33% | -1.24% | |
| Form 10-Q Autonomix Medical, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.95% | -2.64% | |
| Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting | Press release | GlobeNewswire | -0.38% | +0.43% | |
| Form 8-K Autonomix Medical, Inc. For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | -4.88% | -7.18% | |
| Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium | Press release | GlobeNewswire | -4.05% | -8.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AMIX section they belong to.
Where else AMIX is measured.
AMIX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Autonomix Medical, Inc.'s median reaction calculated?
Every labeled AMIX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 237 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of AMIX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AMIX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.